drug
amantadine hydrochloride ER
Marketedupdated 2mo agoby Adamas Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 3 investigational indications.
indications
investigational
Parkinson's Disease
all catalysts(0)
nothing on the calendar yet
Trials studying amantadine hydrochloride ER
- phase2Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).
- phase4Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
- phase2Urinary Excretion of Acetylamantadine by Cancer Patients
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 22, 2028
~1.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (60)
- Aug 23, 2038formulationUS 11065213
- Aug 23, 2038formulationUS 11065213
- Aug 23, 2038method-of-use (U-2106)US 11077073
- Aug 23, 2038method-of-use (U-3180)US 11077073
- Aug 23, 2038method-of-use (U-3180)US 12233033
- Aug 23, 2038method-of-use (U-2224)US 12233033
- Feb 15, 2038method-of-use (U-20)US 10213393
- Feb 15, 2038method-of-use (U-20)US 10213393
- Feb 15, 2038method-of-use (U-20)US 10213393
- Feb 15, 2038method-of-use (U-20)US 10213393
- Feb 15, 2038method-of-use (U-2497)US 10213394
- Feb 15, 2038method-of-use (U-2497)US 10213394
- Feb 15, 2038method-of-use (U-2497)US 10213394
- Feb 15, 2038method-of-use (U-2497)US 10213394
- Feb 15, 2038method-of-use (U-20)US 10500170
- Feb 15, 2038method-of-use (U-20)US 10500170
- Feb 15, 2038method-of-use (U-20)US 10500170
- Feb 15, 2038method-of-use (U-20)US 10500170
- Feb 15, 2038method-of-use (U-2497)US 10500171
- Feb 15, 2038method-of-use (U-2497)US 10500171
- Feb 15, 2038method-of-use (U-2497)US 10500171
- Feb 15, 2038method-of-use (U-2497)US 10500171
- Feb 15, 2038method-of-use (U-2497)US 10500172
- Feb 15, 2038method-of-use (U-2497)US 10500172
- Feb 15, 2038method-of-use (U-2497)US 10500172
- Feb 15, 2038method-of-use (U-2497)US 10500172
- Feb 15, 2038method-of-use (U-2497)US 10512617
- Feb 15, 2038method-of-use (U-2497)US 10512617
- Feb 15, 2038method-of-use (U-2497)US 10512617
- Feb 15, 2038method-of-use (U-2497)US 10512617
- Feb 15, 2038method-of-use (U-2497)US 11890261
- Feb 15, 2038method-of-use (U-2497)US 11890261
- Dec 4, 2034method-of-use (U-2459)US 10154971
- Dec 4, 2034method-of-use (U-2459)US 10154971
- Jun 17, 2034method-of-use (U-2808)US 10646456
- Jun 17, 2034method-of-use (U-2808)US 10646456
- Jun 17, 2034method-of-use (U-3822)US 11903908
- Jun 17, 2034method-of-use (U-3822)US 11903908
- Dec 2, 2030method-of-use (U-2106)US 111978354.4y
- Dec 2, 2030method-of-use (U-2106)US 111978354.4y
- Dec 2, 2030method-of-use (U-2106)US 87413434.4y
- Dec 2, 2030method-of-use (U-2106)US 87413434.4y
- Dec 2, 2030method-of-use (U-2106)US 98677914.4y
- Dec 2, 2030method-of-use (U-2106)US 98677914.4y
- Dec 2, 2030method-of-use (U-2106)US 98677924.4y
- Dec 2, 2030method-of-use (U-2106)US 98677924.4y
- Dec 2, 2030method-of-use (U-2106)US 98677934.4y
- Dec 2, 2030method-of-use (U-2106)US 98677934.4y
- Dec 2, 2030method-of-use (U-2224)US 98779334.4y
- Dec 2, 2030method-of-use (U-2224)US 98779334.4y
- Mar 13, 2030formulationUS 82523313.6y
- Mar 13, 2030formulationUS 82523313.6y
- Mar 13, 2030formulationUS 82523313.6y
- Mar 13, 2030formulationUS 82523313.6y
- Jan 22, 2028method-of-use (U-2105)US 83895781.5y
- Jan 22, 2028method-of-use (U-219)US 83895781.5y
- Jan 22, 2028method-of-use (U-2105)US 83895781.5y
- Jan 22, 2028method-of-use (U-3054)US 83895781.5y
- Jan 22, 2028method-of-use (U-3054)US 83895781.5y
- Jan 22, 2028method-of-use (U-219)US 83895781.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that